Phenylbutyrate induces apoptosis and lipid accumulations via a peroxisome proliferator-activated receptor gamma-dependent pathway

NMR in Biomedicine

Volumn 23, Issue 5, 2010, Pages 473-479

  Milkevitch, Matthew ^a,b   Beardsley, Nancy J ^a   Delikatny, E James ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Differentiation therapy; Glycerophosphocholine; NMR; NMR visible lipids; Peroxisome proliferator activating receptor gamma; Phenylbutyrate

Indexed keywords

APOPTOSIS; CASPASE-3 ACTIVATION; CELL SURVIVAL; DIFFERENTIATION THERAPY; GLYCEROPHOSPHOCHOLINE; H NMR SPECTROSCOPY; LIPID METABOLITES; MTT ASSAYS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PEROXISOME PROLIFERATORS; PRE-INCUBATION; PROSTATE CANCER CELLS;

CHEMICAL ACTIVATION; FLOW CYTOMETRY; LIPIDS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

CELL DEATH;

2 CHLORO 5 NITROBENZANILIDE; BUTYRIC ACID DERIVATIVE; CASPASE 3; CHOLINE; GLYCEROPHOSPHORYLCHOLINE; NUCLEOSIDE TRIPHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHENYLBUTYRATE; PHOSPHORUS 31; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE G1 PHASE; CELL SURVIVAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIPID STORAGE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTON NUCLEAR MAGNETIC RESONANCE;

APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; DNA, NEOPLASM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; LIPID METABOLISM; MALE; PHENYLBUTYRATES; PPAR GAMMA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77953527907     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1484     Document Type: Article

References (47)

1. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H, Glickson JD, Delikatny EJ. Increases in NMR visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochimica Biophysica Acta. 2005; 1734: 1-12.
2. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 1993; 91(5): 2288-2295.
3. Milkevitch M, Jeitner TM, Beardsley N, Delikatny EJ. Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells. Biochimica Biophysica Acta. 2007; 1771: 1531-1539.
4. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 2001; 7(8): 2292-2300.
5. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2002; 8(4): 963-970.
6. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest. New Drugs. Apr 2007; 25(2): 131-138.
7. Castillo M, Martinez-Cayuela M, Zafra MF, Garcia-Peregrin E. Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis. Molec. Cell. Biochem. 1991; 105(1): 21-25.
8. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem. 1996; 66(2): 710-716. (Pubitemid 26036701)
9. Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 2000; 6(11): 4334-4342.
10. Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzalez FJ, Samid D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol. 1996; 52(4): 659-667.
11. Samid D, Wells M, Greene ME, Shen W, Palmer CN, Thibault A. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin. Cancer Res. 2000; 6(3): 933-941.
12. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: PPAR are nuclear receptors at the crossroads of key cellular functions. Progress Lipid Res. 2006; 45: 120-159.
13. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Ann. Rev. Pharmacol. Toxicol. 2000; 40: 491-518.
14. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochem. May 28: 2002; 41(21): 6640-6650.
15. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001; 12: 141-152.
16. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 1997; 129: 35-43.
17. Ray DM, Bernstein SH, Phipps RP. Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin. Immunol. Nov 2004; 113(2): 203-213.
18. Han S, Wada RK, Sidell N. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res. 2001; 61(10): 3998-4002. (Pubitemid 32720962)
19. Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K, Kohri K. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect. Prev. 2008; 32(3): 259-266.
20. Au-Yeung KK, Liu PL, Chan C, Wu WY, Lee SS, Ko JK. Herbal isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPARgamma. Cancer Invest. 2008; 26(7): 708-717.
21. Magenta G, Borenstein X, Rolando R, Jasnis MA. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer. 2008; 8: 47.
22. Liu N, Qiang W, Kuang X, Thuillier P, Lynn WS, Wong PK. The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death. J. Neurovirol. 2002; 8(4): 318-325. (Pubitemid 34982337)
23. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferatoractivated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin. Cancer Res. 2002; 8(4): 1206-1212.
24. Angelucci A, Muzi P, Cristiano L, Millimaggi D, Cimini A, Dolo V, Miano R, Vicentini C, Ceru MP, Bologna M. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate. 2008; 68(6): 588-598. (Pubitemid 351614637)
25. Lea MA, Sura M, Desbordes C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res. 2004; 24(5A): 2765-2771. (Pubitemid 39407154)
26. Cooper WA, Bartier WA, Rideout DC, Delikatny EJ. H-1 NMR visible lipids are induced by phosphonium salts and 5-fluorouracil in human cancer cells. Magn. Reson. Med. 2001; 45(6): 1001-1010.
27. Delikatny EJ, Roman SK, Hancock R, Jeitner TM, Lander CM, Rideout DC, Mountford CE. Tetraphenylphosphonium chloride induced MR-visible lipid accumulation in a malignant human breast cell line. Int. J. Cancer. 1996b; 67: 72-79.
28. Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipid induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res. 2002; 62: 1394-1400. (Pubitemid 34407798)
29. Al-Saffar NM, Titley JC, Robertson D, Clarke PA, Jackson LE, Leach MO, Ronen SM. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br. J. Cancer. 2002; 86(6): 963-970.
30. 1H NMR spectroscopy. Cell Death Differentiat. 2001; 8: 219-224.
31. Di Vito M, Lenti L, Knijn A, Iorio E, D'Agostino F, Molinari A, Calcabrini A, Stringaro A, Meschini S, Arancia G, Bozzi A, Strom R, Podo F. 1H NMR-visible mobile lipid domains correlate with cytoplasmic lipid bodies in apoptotic T-lymphoblastoid cells. Biochimica et Biophysica Acta. 2001; 1530(1): 47-66.
32. Hakumäki JM, Poptani H, Sandmair AM, Ylä-Herttuala S, Kauppinen RA. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis. Nature Med. 1999; 5: 1323-1327. (Pubitemid 29535613)
33. Iorio E, Di Vito M, Spadaro F, Ramoni C, Lococo E, Carnevale R, Lenti L, Strom R, Podo F. Triacsin C inhibits the formation of 1H NMR-visible mobile lipids and lipid bodies in HuT 78 apoptotic cells. Biochimica et Biophysica Acta. 2003; 1634(1-2): 1-14.
34. Sathasivam N, Brammah S, Wright LC, Delikatny EJ. Inhibition of tetraphenylphosphonium-induced NMR-visible lipid accumulation in human breast cells by chlorpromazine. Biochimica et Biophysica Acta. 2003; 1633: 149-160.
35. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochimica et Biophysica Acta (BBA). Molec. Cell Biol. Lipids. 2002; 1585(2-3): 202-212.
36. Wright LC, Groot Obbink KL, Delikatny EJ, Santangelo RT, Sorrell TC. The origin of 1H NMR-visible triacylglycerol in human neutrophils: high fatty acid environments result in preferential sequestration of palmitic acid into plasma membrane triacylglycerol. Eur. J. Biochem. 2000; 267: 68-78.
37. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59(1): 80-84.
38. Glunde K, Ackerstaff E, Natarajan K, Artemov D, Bhujwalla ZM. Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn. Reson. Med. 2002; 48(5): 819-825.
39. Han C, Demetris AJ, Michalopoulos G, Shelhamer JH, Wu T. 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282(4): G586-597.
40. Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH, Wu T. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J. Biol. Chem. 2002; 277(36): 33153-33163.
41. Specty O, Pageaux JF, Dauca M, Lagarde M, Laugier C, Fayard JM. Control of cell proliferation via transduction of sPLA(2)-I activity and possible PPAR activation at the nuclear level. FEBS Lett. 2001; 490(1-2): 88-92.
42. Knowles HJ, te Poele RH, Workman P, Harris AL. Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol. 2006; 71(5): 646-656.
43. Su X, Mancuso DJ, Bickel PE, Jenkins CM, Gross RW. Small interfering RNA knockdown of calcium-independent phospholipases A2 beta or gamma inhibits the hormone-induced differentiation of 3T3-L1 preadipocytes. J. Biol. Chem. 2004; 279(21): 21740-21748.
44. Ye Y, Nishi SP, Manickavasagam S, Lin Y, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostaglandins Other Lipid. Mediat. 2007; 84(1-2): 43-53.
45. Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA, McIntyre TM. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J. Biol. Chem. 2002; 277(15): 13029-13036.
46. Bishop-Bailey D, Warner TD. PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. Faseb J. 2003; 17(13): 1925-1927.
47. Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int. J. Cancer. 2006; 118(2): 396-404.